Evidence map›Paper›PMID 31340775›Full record

ArticleBMC ophthalmology2019

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report.

Jae Hyuk Kim, Hyun Joon Kim, Sun Woong Kim

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jae Hyuk KimDepartment of Ophthalmology, Wonju Severance Christian Hospital, Wonju, South Korea.
Hyun Joon KimDepartment of Ophthalmology, Wonju Severance Christian Hospital, Wonju, South Korea.
Sun Woong KimDepartment of Ophthalmology, Wonju Severance Christian Hospital, Wonju, South Korea. eyedockim@yonsei.ac.kr.
Wonju Severance Christian Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. CASE PRESENTATION: The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftadine 0.25% for allergic conjunctivitis. On first application of the medication, she did not experience any cutaneous reaction. One day later, after the second alcaftadine 0.25% application, both eyelids became swollen, and erythematous changes were evident. On slit-lamp examination, conjunctival injection was noted in the absence of conjunctival swelling or any other findings. Fundus examination was unremarkable. To evaluate the cause of ACD, a patch test was performed and 48 h later was noted to be positive for alcaftadine 0.25%. Based on the positive patch test, the patient was diagnosed with ACD caused by alcaftadine 0.25%. After 9 days of treatment, the swelling and erythema completely resolved.

conclusionsAlthough there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%.

Indexed as

Administration, OralBenzazepinesConjunctivitis, AllergicDermatitis, Allergic ContactFemaleGlucocorticoidsHistamine H1 AntagonistsHumansImidazolesMethylprednisoloneMiddle AgedOphthalmic SolutionsOrbitTomography, X-Ray ComputedalcaftadineBenzazepinesGlucocorticoidsHistamine H1 AntagonistsImidazolesMethylprednisoloneOphthalmic SolutionsAlcaftadine 0.25%Allergic conjunctivitisAllergic contact dermatitis

Identifiers

PMID31340775
PMCPMC6657074
OpenAlexW2963479487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.